[go: up one dir, main page]

MX2017005481A - Variantes de interferon a2b. - Google Patents

Variantes de interferon a2b.

Info

Publication number
MX2017005481A
MX2017005481A MX2017005481A MX2017005481A MX2017005481A MX 2017005481 A MX2017005481 A MX 2017005481A MX 2017005481 A MX2017005481 A MX 2017005481A MX 2017005481 A MX2017005481 A MX 2017005481A MX 2017005481 A MX2017005481 A MX 2017005481A
Authority
MX
Mexico
Prior art keywords
domain
ifna2b
aglycosylated
interferon
seq
Prior art date
Application number
MX2017005481A
Other languages
English (en)
Other versions
MX393988B (es
Inventor
Clarke Adam
Pollard Matthew
Behrens Collette
Doyle Anthony
Domagala Teresa
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55851917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005481(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904326A external-priority patent/AU2014904326A0/en
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Publication of MX2017005481A publication Critical patent/MX2017005481A/es
Publication of MX393988B publication Critical patent/MX393988B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona un polipéptido de fusión que comprende un primer dominio y un segundo dominio, en el que el primer dominio comprende un ligando polipeptídico que se une a un antígeno asociado a la superficie celular y el segundo dominio comprende interferón a 2b (IFNa2b) aglicosilado que tiene una secuencia de SEQ ID NO: 1 o SEQ ID NO: 2. El IFNa2b aglicosilado comprende además una o más sustituciones o deleciones de aminoácidos que atenúan la actividad del IFNa2b aglicosilado.
MX2017005481A 2014-10-29 2015-10-23 Variantes de interferon a2b. MX393988B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014904326A AU2014904326A0 (en) 2014-10-29 Interferon alpha 2b variants
PCT/AU2015/050654 WO2016065409A1 (en) 2014-10-29 2015-10-23 INTERFERON α2B VARIANTS

Publications (2)

Publication Number Publication Date
MX2017005481A true MX2017005481A (es) 2017-10-26
MX393988B MX393988B (es) 2025-03-24

Family

ID=55851917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005481A MX393988B (es) 2014-10-29 2015-10-23 Variantes de interferon a2b.

Country Status (18)

Country Link
US (3) US10544199B2 (es)
EP (1) EP3212216A4 (es)
JP (2) JP6730271B2 (es)
KR (1) KR102639037B1 (es)
CN (1) CN107106656B (es)
AU (1) AU2015337858B2 (es)
CA (1) CA2965414C (es)
CL (1) CL2017001070A1 (es)
CO (1) CO2017004318A2 (es)
EA (1) EA037749B1 (es)
IL (1) IL251822B2 (es)
MX (1) MX393988B (es)
PE (1) PE20170908A1 (es)
PH (1) PH12017500785A1 (es)
SG (1) SG11201703251TA (es)
UA (1) UA125637C2 (es)
WO (1) WO2016065409A1 (es)
ZA (1) ZA201702891B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JP6286532B2 (ja) 2013-04-29 2018-02-28 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3299466B1 (en) * 2013-07-18 2019-09-11 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (en) * 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
DK3411065T3 (da) * 2016-02-05 2021-07-05 Orionis Biosciences BV Clec9a-bindingsmidler
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US20200354424A1 (en) * 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
CA3095310A1 (en) * 2018-03-28 2019-10-03 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
AU2019336426A1 (en) * 2018-09-04 2021-04-29 Nanjing Umab-Biopharma Co., Ltd. Fusion protein and its application in preparing medicine for treating tumor and/or viral infection
US12162947B2 (en) 2018-09-04 2024-12-10 Nanjing Umab-Biopharma Co., Ltd. Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
AR117715A1 (es) 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
US11767353B2 (en) * 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US20250134962A1 (en) * 2021-08-12 2025-05-01 Shanghai Ttm-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
AU2023274047A1 (en) * 2022-05-18 2024-12-05 Cephalon, LLC Anti-cd38 fusion protein formulation
EP4532010A1 (en) 2022-05-27 2025-04-09 Takeda Pharmaceutical Company Limited Dosing of cd38-binding fusion protein
WO2024069240A2 (en) 2022-09-29 2024-04-04 Takeda Pharmaceutical Company Limited Cd38-binding fusion protein combination therapy
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU2071695A (en) 1994-03-17 1995-10-03 Merck Patent Gmbh Anti-EGFR single-chain FVS and anti-EGFR antibodies
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DE69737188T2 (de) 1996-05-04 2007-10-11 Astrazeneca Ab Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
DE69942636D1 (de) 1998-12-09 2010-09-09 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
KR100731826B1 (ko) * 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
CA2362670A1 (en) 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
AU2001265418B2 (en) 2000-06-22 2006-03-30 Biogen Idec Inc. Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
MX349009B (es) 2001-01-05 2017-07-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ES2328234T3 (es) 2001-07-03 2009-11-11 Genentech, Inc. Anticuerpos dr4 humanos y utilizaciones de los mismos.
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100668538B1 (ko) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
AU2003267700A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2516293A1 (en) 2003-02-18 2004-09-02 Tim Jones Fusion proteins of interferon alpha muteins with improved properties
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
JP5743368B2 (ja) * 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
PL2511297T3 (pl) 2004-02-06 2015-08-31 Morphosys Ag Ludzkie przeciwciała anty-CD38 i ich zastosowania
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
MX2007014889A (es) 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
WO2007000769A2 (en) 2005-06-29 2007-01-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS
EP2397497A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
US20070190068A1 (en) 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
CA2627890A1 (en) 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
FR2905375A1 (fr) 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
JP5562031B2 (ja) 2006-09-18 2014-07-30 ゼンコー・インコーポレイテッド Ｈｍ１．２４を標的とする最適化抗体
AU2007302448C1 (en) 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
US8248984B2 (en) 2007-06-20 2012-08-21 I Squared Llc System and method for interfacing devices
EA201000053A1 (ru) * 2007-08-01 2010-08-30 Глаксо Груп Лимитед Новые антитела
US9364557B2 (en) 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
KR101759460B1 (ko) 2007-09-21 2017-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
CA2708291A1 (en) * 2007-12-10 2009-06-18 National Research Council Of Canada Production of recombinant interferon proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BRPI0821447A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
EA024695B1 (ru) 2009-03-16 2016-10-31 Сефалон Острэйлиа Пти Лтд. Гуманизированные антитела с противоопухолевой активностью
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
US8909257B2 (en) 2010-06-19 2014-12-09 Qualcomm Incorporated Positioning protocol conveyance
SG188345A1 (en) 2010-09-27 2013-04-30 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
BR112014007426B1 (pt) * 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
NZ756727A (en) * 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
HUE049945T2 (hu) 2012-03-03 2020-11-30 Immungene Inc Módosított antitest-interferon mutáns fúziós molekulák
US9783589B2 (en) 2012-08-13 2017-10-10 Immungene Inc Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
JP2016511712A (ja) 2013-01-25 2016-04-21 バイエル・マテリアルサイエンス・アクチェンゲゼルシャフトＢａｙｅｒ ＭａｔｅｒｉａｌＳｃｉｅｎｃｅ ＡＧ 体積ホログラムと印刷されたフィーチャを有するセキュリティ要素
JP6286532B2 (ja) 2013-04-29 2018-02-28 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (en) * 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
CA3030926A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy

Also Published As

Publication number Publication date
MX393988B (es) 2025-03-24
CL2017001070A1 (es) 2018-01-26
JP6730271B2 (ja) 2020-07-29
NZ731203A (en) 2024-09-27
US11319356B2 (en) 2022-05-03
IL251822A0 (en) 2017-06-29
ZA201702891B (en) 2018-08-29
EA201790934A1 (ru) 2017-09-29
UA125637C2 (uk) 2022-05-11
US20200102364A1 (en) 2020-04-02
US10544199B2 (en) 2020-01-28
CO2017004318A2 (es) 2017-09-20
CN107106656A (zh) 2017-08-29
AU2015337858A1 (en) 2017-05-11
US20220220184A1 (en) 2022-07-14
PE20170908A1 (es) 2017-07-12
SG11201703251TA (en) 2017-05-30
AU2015337858B2 (en) 2020-09-24
CA2965414A1 (en) 2016-05-06
JP2020103319A (ja) 2020-07-09
JP2017534282A (ja) 2017-11-24
WO2016065409A1 (en) 2016-05-06
CA2965414C (en) 2024-01-09
EA037749B1 (ru) 2021-05-18
KR20170077185A (ko) 2017-07-05
IL251822B2 (en) 2023-03-01
IL251822B (en) 2022-11-01
EP3212216A4 (en) 2018-04-18
KR102639037B1 (ko) 2024-02-20
CN107106656B (zh) 2025-08-26
BR112017008880A2 (pt) 2018-07-10
EP3212216A1 (en) 2017-09-06
JP6957666B2 (ja) 2021-11-02
US20160122410A1 (en) 2016-05-05
PH12017500785A1 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
MX2017005481A (es) Variantes de interferon a2b.
AR131695A2 (es) Anticuerpo que se une a miostatina latente y ácido nucleico que lo codifica
BR112015020516A2 (pt) composições e métodos para imunoterapia
MX2016001093A (es) Nanoemulsion de aminosilicona.
MX2016001094A (es) Nanoemulsion de aminosilicona.
CY1121891T1 (el) Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας
MX382929B (es) Polipéptido heterodimerizado.
MX2017006866A (es) Pares de unión para producción de péptidos.
SG10201909716RA (en) Modified j-chain
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
BR112016023517A2 (pt) produção de células t projetadas por transpóson sleeping beauty acoplado com seleção de metotrexato
MX387180B (es) Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
MX2020012816A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
MX2017008449A (es) Polipeptido de pirina y modulacion inmune.
MX2018001825A (es) Variantes y conjugados de albumina.
MX387336B (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
IN2014DE02404A (es)
JO3607B1 (ar) مضادات الأجسام المضادة لإنترفيرون ألفا وأوميجا
CR20180445A (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
IN2014MU01248A (es)
AR101555A1 (es) ANTICUERPOS DIRIGIDOS AL RECEPTOR IIB DE Fc g Y AL RECEPTOR DE Fc e